Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210270900> ?p ?o ?g. }
- W4210270900 endingPage "115045" @default.
- W4210270900 startingPage "115045" @default.
- W4210270900 abstract "Goiter with hypothyroidism occurs in several thyroid diseases. Xiao-Luo-Wan (XLW), which contains Scrophularia ningpoensis Hemsl., Fritillaria thunbergii Miq. and Ostrea gigas Thunberg, has been used as an effective Chinese medicine for the treatment of goiters in China for hundreds of years. Based on clinical observations and experimental studies, XLW also exerts a certain effect on hypothyroidism. However, the therapeutic mechanism of XLW remains unclear.The present study aimed to investigate the therapeutic effect of XLW on propylthiouracil (PTU)-induced goiter with hypothyroidism in rats and to uncover the underlying molecular mechanism using ultra high-performance liquid chromatography-mass spectrometry (UPLC/MS), network pharmacology, and molecular docking simulations.After successful modeling, the remaining rats were randomly divided into a model group, an Euthyrox group, an XLW group, and a control group. The corresponding drugs were given by gavage for four consecutive weeks. The growth status was monitored, the relative thyroid weight was calculated, and the total serum T3, T4, and TSH content were detected. Hematoxylin-eosin (H&E) staining was used to observe the pathological changes in the thyroid glands. The chemical components of the XLW were identified by UPLC/MS and the putative targets of XLW were predicted using multiple databases. We performed network pharmacology based on the intersection of goiter/hypothyroidism-related targets and XLW targets. Then, we performed KEGG pathway enrichment analysis, and key targets were further screened using protein-protein interaction (PPI) networks. Finally, molecular docking was used to predict the binding ability of XLW identified components and the key targets.XLW significantly increased the levels of T3 and T4, and reduced TSH, increased body weight, and decreased swollen thyroid glands in PTU-induced rats. XLW promoted the morphological recovery of thyroid follicles and epithelial cells. Twenty-one main chemical components of XLW were identified using UPLC/MS. 270 potential gene targets of XLW and 717 known targets of goiter/hypothyroidism disease were obtained by searching the Traditional Chinese Medicine Systems Pharmacology Database (TCMSP), Swiss Target Prediction, and UniProt databases. A total of 83 KEGG pathways were enriched with phosphatidylinositol 3-kinase-protein kinase B (PI3K-AKT) and RAS signaling pathways. PPI analysis revealed nine key targets of kinase-protein kinase B (AKT) 1, interleukin (IL) 6, vascular endothelial growth factor A (VEGFA), tumor necrosis factor (TNF), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), epidermal growth factor receptor (EGFR), GTPase HRas (HRAS), matrix metalloproteinase (MMP) 9, and heat shock protein 90 alpha family class A member 1 (HSP90AA1). Molecular docking verified which drug components had good binding ability to key targets (all ≤5 kcal/mol).For PTU-induced goiter with hypothyroidism in rats, XLW improves thyroid function, reduces goiter, increases body weight, and promotes the recovery of thyroid follicles and epithelial cells. The underlying molecular mechanism suggests that XLW may regulate thyroid hormone signaling by regulating the PI3K-AKT, RAS, and other signaling pathways. This study provides a pharmacological and biological basis for using XLW to treat goiter with hypothyroidism." @default.
- W4210270900 created "2022-02-08" @default.
- W4210270900 creator A5004355471 @default.
- W4210270900 creator A5012381307 @default.
- W4210270900 creator A5033930770 @default.
- W4210270900 creator A5051560521 @default.
- W4210270900 creator A5052675926 @default.
- W4210270900 creator A5054997017 @default.
- W4210270900 creator A5069191363 @default.
- W4210270900 creator A5076854953 @default.
- W4210270900 creator A5083392344 @default.
- W4210270900 date "2022-05-01" @default.
- W4210270900 modified "2023-10-15" @default.
- W4210270900 title "Xiao-Luo-Wan treats propylthiouracil-induced goiter with hypothyroidism in rats through the PI3K-AKT/RAS pathways based on UPLC/MS and network pharmacology" @default.
- W4210270900 cites W1747119434 @default.
- W4210270900 cites W1828629754 @default.
- W4210270900 cites W1967914320 @default.
- W4210270900 cites W1978653276 @default.
- W4210270900 cites W1983353299 @default.
- W4210270900 cites W1988997384 @default.
- W4210270900 cites W1999600172 @default.
- W4210270900 cites W2004260518 @default.
- W4210270900 cites W2006180904 @default.
- W4210270900 cites W2007224388 @default.
- W4210270900 cites W2021932599 @default.
- W4210270900 cites W2023846971 @default.
- W4210270900 cites W2025112777 @default.
- W4210270900 cites W2027335830 @default.
- W4210270900 cites W2029090528 @default.
- W4210270900 cites W2033259043 @default.
- W4210270900 cites W2037933674 @default.
- W4210270900 cites W2049736650 @default.
- W4210270900 cites W2083150841 @default.
- W4210270900 cites W2111877563 @default.
- W4210270900 cites W2114499789 @default.
- W4210270900 cites W2124679671 @default.
- W4210270900 cites W2143615105 @default.
- W4210270900 cites W2153159302 @default.
- W4210270900 cites W2165806416 @default.
- W4210270900 cites W2166154813 @default.
- W4210270900 cites W2171913400 @default.
- W4210270900 cites W2317721149 @default.
- W4210270900 cites W2323824213 @default.
- W4210270900 cites W2341456237 @default.
- W4210270900 cites W2460688549 @default.
- W4210270900 cites W2470848484 @default.
- W4210270900 cites W2474747771 @default.
- W4210270900 cites W2555800891 @default.
- W4210270900 cites W2720897370 @default.
- W4210270900 cites W2744377419 @default.
- W4210270900 cites W2767891136 @default.
- W4210270900 cites W2898364362 @default.
- W4210270900 cites W2900569176 @default.
- W4210270900 cites W2928665623 @default.
- W4210270900 cites W2946412700 @default.
- W4210270900 cites W2955341169 @default.
- W4210270900 cites W2965968936 @default.
- W4210270900 cites W2966200315 @default.
- W4210270900 cites W2975648456 @default.
- W4210270900 cites W3015204302 @default.
- W4210270900 cites W3095882419 @default.
- W4210270900 cites W3096828292 @default.
- W4210270900 cites W3121804669 @default.
- W4210270900 cites W3136918052 @default.
- W4210270900 cites W4243225672 @default.
- W4210270900 cites W4254365872 @default.
- W4210270900 doi "https://doi.org/10.1016/j.jep.2022.115045" @default.
- W4210270900 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35101570" @default.
- W4210270900 hasPublicationYear "2022" @default.
- W4210270900 type Work @default.
- W4210270900 citedByCount "4" @default.
- W4210270900 countsByYear W42102709002022 @default.
- W4210270900 countsByYear W42102709002023 @default.
- W4210270900 crossrefType "journal-article" @default.
- W4210270900 hasAuthorship W4210270900A5004355471 @default.
- W4210270900 hasAuthorship W4210270900A5012381307 @default.
- W4210270900 hasAuthorship W4210270900A5033930770 @default.
- W4210270900 hasAuthorship W4210270900A5051560521 @default.
- W4210270900 hasAuthorship W4210270900A5052675926 @default.
- W4210270900 hasAuthorship W4210270900A5054997017 @default.
- W4210270900 hasAuthorship W4210270900A5069191363 @default.
- W4210270900 hasAuthorship W4210270900A5076854953 @default.
- W4210270900 hasAuthorship W4210270900A5083392344 @default.
- W4210270900 hasConcept C104317684 @default.
- W4210270900 hasConcept C126322002 @default.
- W4210270900 hasConcept C134018914 @default.
- W4210270900 hasConcept C142724271 @default.
- W4210270900 hasConcept C150194340 @default.
- W4210270900 hasConcept C152724338 @default.
- W4210270900 hasConcept C162317418 @default.
- W4210270900 hasConcept C185592680 @default.
- W4210270900 hasConcept C188947578 @default.
- W4210270900 hasConcept C204787440 @default.
- W4210270900 hasConcept C2775960720 @default.
- W4210270900 hasConcept C2776254400 @default.
- W4210270900 hasConcept C526584372 @default.
- W4210270900 hasConcept C55493867 @default.
- W4210270900 hasConcept C71924100 @default.